Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus

被引:23
|
作者
Iwabuchi, Atsushi [1 ]
Kamoda, Tomohiro [1 ]
Saito, Makoto [1 ]
Nozue, Hiroki [2 ]
Izumi, Isho [3 ]
Hirano, Takeki [4 ]
Sumazaki, Ryo [1 ]
机构
[1] Univ Tsukuba, Fac Med, Dept Pediat, Tsukuba, Ibaraki 3058575, Japan
[2] Tsukuba Med Ctr Hosp, Dept Pediat, Ibaraki, Japan
[3] Ibaraki Childrens Hosp, Dept Pediat, Ibaraki, Japan
[4] Hirano Childrens Clin, Dept Pediat, Ibaraki, Japan
来源
关键词
adiponectin; CD26; dipeptidyl peptidase 4; type 1 diabetes mellitus; CELL-ACTIVATION ANTIGEN; BODY-MASS INDEX; INSULIN-RESISTANCE; GLYCEMIC CONTROL; YOUNG-PEOPLE; ADIPONECTIN; OBESITY; CD26; ASSOCIATION; SITAGLIPTIN;
D O I
10.1515/jpem-2013-0122
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: It is poorly understood whether dipeptidyl peptidase 4 (DPP4) activity is altered and how DPP4 contributes to glycemic control in patients with type 1 diabetes mellitus (T1DM). Aim: The aim of this study was to measure serum DPP4 activity and to assess its relationships to metabolic variables in T1DM children. Methods: Serum DPP4 activity was determined using a fluorometric assay in 43 T1DM and 26 control children. Results: Serum DPP4 activity was significantly higher in T1DM children than in controls (3.57 +/- 0.99 vs. 2.67 +/- 0.77 U/mL, p<0.001). In the T1DM children, DPP4 activity was not correlated with HbA(1c), blood glucose, or diabetes duration. A significant negative correlation was found between DPP4 activity and serum adiponectin levels in the T1DM group (r=-0.35, p<0.05). Conclusions: Serum DPP4 activity was increased in the T1DM children, whereas it was not associated with glycemic control. Given the negative correlation between serum DPP4 and adiponectin levels, further investigations are warranted to elucidate the role of DPP4 on insulin sensitivity in T1DM children.
引用
收藏
页码:1093 / 1097
页数:5
相关论文
共 50 条
  • [21] Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Jarvis, Courtney I.
    Cabrera, Adriana
    Charron, Derek
    [J]. ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1532 - 1539
  • [22] Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Johnson, Kathryn M. S.
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (04) : 455 - 463
  • [23] Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes
    Duvnjak, Lea
    Perkovic, Matea Nikolac
    Blaslov, Kristina
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (01) : 218 - 222
  • [24] Association between HbA1c and dipeptidyl peptidase IV activity in type 2 diabetes mellitus
    Belle, Luziane Potrich
    Rodrigues Bitencourt, Paula Eliete
    De Bona, Karine Santos
    Moresco, Rafael Noal
    Moretto, Maria Beatriz
    [J]. CLINICA CHIMICA ACTA, 2012, 413 (11-12) : 1020 - 1021
  • [25] ACUTE EFFECTS OF EXERCISE ON POST-PRANDIAL ACTIVITY OF DIPEPTIDYL PEPTIDASE-4 IN TYPE 2 DIABETES MELLITUS
    Sousa, N. M.
    Silva, L. R.
    Barros, F. C.
    Fraga, M. Z.
    Coelho, B.
    Silva Filho, W. G.
    Barauna, V. G.
    [J]. CARDIOLOGY, 2017, 137 : 321 - 321
  • [26] Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
    Driessen, Johanna H. M.
    van Onzenoort, Hein A. W.
    Henry, Ronald M. A.
    Lalmohamed, Arief
    van den Bergh, Joop P.
    Neef, Cees
    Leufkens, Hubert G. M.
    de Vries, Frank
    [J]. BONE, 2014, 68 : 124 - 130
  • [27] Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review
    Samoilova, Iuliia G.
    Vaizova, Olga E.
    Stankova, Anastasia E.
    Matveeva, Mariia, V
    Podchinenova, Daria, V
    Kudlay, Dmitry A.
    Borozinets, Anastasiia A.
    Filippova, Tatyana A.
    Grishkevich, Ivan R.
    Partala, Anastasia, V
    Gerasimova, Diana A.
    [J]. TERAPEVTICHESKII ARKHIV, 2024, 96 (01): : 63 - 67
  • [28] Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
    Esaki, Hiroki
    Tachi, Tomoya
    Goto, Chitoshi
    Sugita, Ikuto
    Kanematsu, Yuta
    Yoshida, Aki
    Saito, Kosuke
    Noguchi, Yoshihiro
    Ohno, Yuki
    Aoyama, Satoshi
    Yasuda, Masahiro
    Mizui, Takashi
    Yamamura, Masumi
    Teramachi, Hitomi
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [29] Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
    Chen, Xiao-Wu
    He, Zhi-Xu
    Zhou, Zhi-Wei
    Yang, Tianxin
    Zhang, Xueji
    Yang, Yin-Xue
    Duan, Wei
    Zhou, Shu-Feng
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2015, 42 (10) : 999 - 1024
  • [30] Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus
    Ndefo, Uche Anadu
    Okoli, Okwuchukwu
    Erowele, Goldina
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (02) : 103 - 109